A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis.
about
Non-steroid agents for idiopathic pulmonary fibrosisImmunomodulatory agents for idiopathic pulmonary fibrosisHeterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosisAn official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and managementComputer-assisted detection of infectious lung diseases: a review.Safety and efficacy of recombinant gamma interferon in the treatment of systemic sclerosis.Compartmentalized expression of c-FLIP in lung tissues of patients with idiopathic pulmonary fibrosisPredicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and managementDyspnea and decreased variability of breathing in patients with restrictive lung disease.Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2.Increased expression of the interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis. A potential mechanism for the recruitment and activation of neutrophils in lung fibrosisA monoclonal antibody to the carboxyterminal domain of procollagen type I visualizes collagen-synthesizing fibroblasts. Detection of an altered fibroblast phenotype in lungs of patients with pulmonary fibrosisVarious diffuse infiltrative lung diseases: high resolution computed tomography appearances.Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis.Expression of glucocorticoid receptors alpha and beta in steroid sensitive and steroid insensitive interstitial lung diseases.Long-term respiratory health effects of the herbicide, paraquat, among workers in the Western Cape.Models of disease behavior in idiopathic pulmonary fibrosis.Ameliorating effect of an interferon inducer polyinosinic-polycytidylic acid on bleomycin-induced lung fibrosis in hamsters. Morphologic and biochemical evidence.Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy.Nonspecific interstitial pneumonia/fibrosis: clinical manifestations, histologic and radiologic features.Idiopathic pulmonary fibrosis: can cell mediated immunity markers predict clinical outcome?Abnormal deposition of collagen/elastic vascular fibres and prognostic significance in idiopathic interstitial pneumonias.Emerging drugs for idiopathic pulmonary fibrosis.The correlation of symptoms, pulmonary function tests and exercise testing with high-resolution computed tomography in patients with idiopathic interstitial pneumonia in a tertiary care hospital in South India.Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis.Pulmonary function testing in idiopathic interstitial pneumoniasHigh resolution computed tomography as a predictor of lung histology in systemic sclerosis.Outcome Measures for Clinical Trials in Interstitial Lung Diseases.FEV1 over time in patients with connective tissue disease-related bronchiolitis.The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis.The six-minute walk test in patients with pulmonary sarcoidosis.Endothelin-1 in idiopathic pulmonary fibrosis.Macrophage derived chemokine (CCL22), thymus and activation-regulated chemokine (CCL17), and CCR4 in idiopathic pulmonary fibrosisPredicting survival of patients with idiopathic pulmonary fibrosis using GAP score: a nationwide cohort study.Invariant natural killer T (iNKT) cell exhaustion in sarcoidosis.Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trialInterstitial and vascular type V collagen morphologic disorganization in usual interstitial pneumonia.Elderly-onset sarcoidosis: prevalence, clinical course, and treatment.Antibody responses after lung immunization.
P2860
Q24235478-95A20CC9-8FF7-4518-9812-CB9B5BB7AFE6Q24248714-08560939-C5B6-4A50-A897-B194829D55CBQ27316615-CE47C154-6264-44B1-A798-A4603E3B6D66Q28308246-0D526B62-E8A2-4A28-8427-F8204A9A9599Q30459495-5DD2E142-1C31-46CC-8509-7C36868B0D0BQ33579356-3799C481-53F8-4574-A64C-7988DB93984DQ33658780-21953670-011D-48CD-890B-5269A1B18332Q33955628-A91B919A-6889-4F17-B792-220099CCA269Q34000433-1E8165E9-36D3-4996-8069-8AA57D105F59Q34126868-0F0577BA-6E97-45AB-AE21-B3E1B3FC8325Q34211740-E30A337C-15E1-48D8-9C1B-5EF220BC3732Q34213002-319E4B02-23BC-4C96-BE56-0BE46D2D2B4DQ34546028-58DB0B5A-CD32-4250-B978-EBF8B61DF6BBQ34570345-EF81796B-078C-4BB8-A2B2-30AD678AE706Q35533486-D6D33661-800B-4E5C-8196-A815191B357EQ35536857-7576CDBB-AD6B-45C7-8FE5-54A1AE20D92EQ35561309-077DB3E5-B502-4221-B79E-A01F4B1DB609Q35786052-F209F8A9-6A9E-40AA-92ED-B48F998D17F8Q35819150-0671BC91-05A6-4F28-ACC8-09C58F30B6E1Q35841561-B717C6A3-654E-4671-A985-53F951928FD4Q35938750-3D859333-3ADF-41DC-B15C-D66A41B86A4AQ36223858-CDF0BA70-2506-4391-932F-F8B952749AB0Q36225646-28572C4C-5E75-4071-BF11-4A690C0FB476Q36302828-AE981098-DE7F-4963-B86E-0FC57569B609Q36330724-81BE3228-8C70-4563-8597-2B4357ADB624Q36411185-A54995D8-63CF-470F-9FDB-DBCCBB356D24Q36493952-C3CC4F47-AA14-459E-9DB2-4CAE0AEA8F02Q36564691-5FB289D5-5A48-49B8-989C-6E7AE3D20719Q36726418-753A34AC-3BF8-4CA5-96B4-F3C104C60116Q36969005-0380D943-A3B0-4A7B-B2A4-E315B34C4A61Q37111866-CAD3CDF1-DE19-4830-8254-1FC202EB1872Q37237822-1EB03940-A597-4FFD-9EF1-4A2C7A4C4B19Q37260266-739B568F-5439-4746-839C-8C2C9F0DC9CBQ37341261-57EFA974-C1DA-4989-92EE-58BF2D0254F9Q37349367-2E5236CC-5CA5-47F6-8093-659030E188F6Q37406517-32675B31-3B65-47CF-A860-FE5EBE9EBABAQ37414226-2CC7493B-4702-40B4-B980-B592C38D22F6Q37644112-7EF5B427-39A1-420D-AC84-631FCC4B76DBQ38160360-00F518FF-A50B-4982-BF6E-C348D8BD66F6Q38188585-4A279A6C-A02E-4A0E-9C9D-FF6882A6DFB4
P2860
A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
1986年论文
@zh
1986年论文
@zh-cn
name
A clinical, radiographic, and ...... idiopathic pulmonary fibrosis.
@en
A clinical, radiographic, and ...... idiopathic pulmonary fibrosis.
@nl
type
label
A clinical, radiographic, and ...... idiopathic pulmonary fibrosis.
@en
A clinical, radiographic, and ...... idiopathic pulmonary fibrosis.
@nl
prefLabel
A clinical, radiographic, and ...... idiopathic pulmonary fibrosis.
@en
A clinical, radiographic, and ...... idiopathic pulmonary fibrosis.
@nl
P2093
P1476
A clinical, radiographic, and ...... idiopathic pulmonary fibrosis.
@en
P2093
Cherniack RM
Schwarz MI
Stanford RE
Waldron JA
Watters LC
P304
P356
10.1164/ARRD.1986.133.1.97
P577
1986-01-01T00:00:00Z